How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape

As October’s Eczema Awareness Month draws renewed attention to atopic dermatitis (AD), patient care continues to evolve rapidly, with regulatory milestones, midstage trial readouts, and a high-profile program discontinuation all landing within the same several-month window. For dermatologists managing moderate to severe disease, the practical implications span dosing flexibility for existing biologics, an expanding roster of pediatric options, and a pipeline that is diversifying well beyond the IL-4/IL-13 axis.

Less Frequent Dosing for an Established Biologic

The FDA has approved an every-8-week maintenance dosing option for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company), extending the IL-13–targeting monoclonal antibody's flexibility for adults and adolescents 12 years and older weighing at least 40 kg with moderate to severe AD.¹ The approval adds to a regimen previously limited to once-monthly maintenance dosing, meaning eligible patients can now maintain disease control with as few as 6 maintenance injections a year after completing induction.

The decision rests on longitudinal exposure-response modeling and the phase 3 ADjoin (NCT04392154) extension, which evaluated open-label lebrikizumab 250 mg every 4 weeks or every 8 weeks over 32 weeks in patients who had participated in the ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967), ADore (NCT04250350), and ADopt-VA (NCT04626297) trials. No patients discontinued treatment because of adverse events during the extension, and the most frequently reported adverse reactions were conjunctivitis, injection site reactions, and herpes zoster. Christopher Bunick, MD, PhD, associate professor of dermatology at the Yale School of Medicine and editor in chief of Dermatology Times, called the change "a significant differentiator among IL-13– and IL-4R–targeted biologics" that should factor into shared clinical decision-making.

Topical and Pediatric Access Continues to Widen

Regulatory momentum in AD isn't limited to injectables. The FDA has accepted Arcutis Biotherapeutics' supplemental new drug application to expand the indication for roflumilast cream 0.05% (Zoryve), a once-daily, steroid-free PDE4 inhibitor, to include infants aged 3 months to younger than 2 years with mild to moderate AD. The Prescription Drug User Fee Act target action date is February 23, 2027, and no advisory committee meeting is currently planned.² The filing is supported by the phase 2 INTEGUMENT-INFANT study (NCT06998056), in which nearly half of treated infants achieved a validated Investigator Global Assessment (vIGA) score of clear or almost clear at week 4, along with rapid improvements in itch. If cleared, the label would push a nonsteroidal topical option down to one of the youngest AD populations, an age group with few advanced, FDA-approved alternatives.

Pediatric development is also advancing on the systemic side. LEO Pharma's phase 2 TRAPEDS 1 trial (NCT05388760) met its primary pharmacokinetic objective for tralokinumab (Adbry/Adtralza) in children aged 6 to 11 years with moderate to severe AD, with an exposure profile consistent with adult and adolescent data and no new safety signals over as long as 172 weeks of treatment.³ Efficacy findings will be reported separately, and a phase 3 trial, TRAPEDS 2 (NCT06311682), is already underway in younger children and infants. Tralokinumab was recently included with a strong recommendation in the American Academy of Dermatology's first pediatric AD guidelines, alongside dupilumab, lebrikizumab, and nemolizumab.⁴

More Topical Innovation: GX-03 Broadens Its Target Population

Among nonsteroidal topicals in development, Turn Therapeutics' GX-03 has drawn attention for interim phase 2 data suggesting activity across a wider range of disease severity than initially anticipated.⁵ In patients with lower baseline Eczema Area and Severity Index (EASI) scores, indicating milder disease by that measure, GX-03 outperformed vehicle on vIGA for AD treatment success at week 4 by a wide margin, according to the company. The advantage was even more pronounced among patients with elevated baseline itch scores despite modest EASI scores—a population typically underserved by severity metrics that don't capture functional burden. Based on these findings, Turn Therapeutics has finalized a stage 2 design enrolling approximately 120 to 135 patients across the full baseline EASI spectrum, using the Hochberg multiple-testing procedure to evaluate 4 coprimary efficacy end points.

"I really think there is an opportunity here to not just benefit the people that have a larger overall inflammatory burden on their body, but to potentially keep people from needing systemics in the future," Bradley Burnam, founder and CEO of Turn Therapeutics, said in an exclusive interview with Dermatology Times.

Oral and Novel-Mechanism Systemic Agents Advance

The race for an effective oral alternative to injectable biologics is intensifying. Kymera Therapeutics completed enrollment in its phase 2b BROADEN2 trial (NCT07217015) of KT-621, an oral STAT6 degrader, nearly 6 months ahead of schedule, moving top-line data in moderate to severe AD up to year-end 2026, with a planned phase 3 start by mid-2027.⁶ KT-621 already carries FDA fast track designation, and the company has framed the oral, mechanism-targeted approach as a potential solution for the substantial share of biologic-eligible patients who decline injectable therapy out of needle hesitancy.

"Having an oral drug that could do something similar to dupilumab has been sort of a Holy Grail, if you will, in the atopic dermatitis field,” Jared Gollob, MD, an executive advisor at Kymera Therapeutics, told Dermatology Times. “Our hope is [that] if we have an oral drug that eventually is able to show substantial activity and safety potentially comparable to dupilumab, but now it's an oral drug, this could make the drug available to many more patients.”

A structurally different mechanism also reported encouraging results: Nektar Therapeutics published 16-week induction data from the phase 2b REZOLVE-AD trial (NCT06136741) of rezpegaldesleukin, a regulatory T-cell (T-reg) stimulator, in The Lancet.⁷ All 3 dosing regimens met the primary end point, producing statistically significant, dose-dependent reductions in EASI scores compared with placebo, with the highest-dose arm reaching approximately double the placebo response. The trial represents the first large, randomized, placebo-controlled study to support T-reg modulation as a viable mechanism in a chronic inflammatory skin disease, and phase 3 ZENITH AD trials (NCT07690371; NCT07711418) are already underway.

A Notable Setback

Not every mechanism has panned out. Sanofi recently discontinued development of amlitelimab, its OX40L inhibitor, in moderate to severe AD, opting not to pursue regulatory submission despite durable long-term response data from the phase 3 ESTUARY extension study (NCT06407934).⁸ The company concluded the overall efficacy and safety profile did not sufficiently differentiate amlitelimab from existing standard-of-care therapies. The decision follows the March 2026 discontinuation of rocatinlimab, another anti-OX40 pathway agent, due to malignancy safety concerns, leaving the OX40/OX40L class without an active AD program and narrowing near-term pipeline diversity, even as IL-4/IL-13, Janus kinase, oral STAT6, and T-reg approaches continue to advance.⁹ Bunick called the loss "a tremendous loss for patients," noting the hype around a mechanism that had promised disease modification with less frequent dosing.

Looking Ahead

Taken together, these developments point to a treatment landscape that is simultaneously maturing and diversifying. Established biologics are gaining dosing flexibility and pediatric indications; novel oral and topical agents are advancing toward broader severity ranges; and mechanistically distinct approaches, like T-reg modulation, are entering late-stage development, even as some pathways, like OX40L blockade, fall away. For clinicians, the coming 12 to 18 months should bring top-line data, continued phase 3 progress, and potential FDA approvals, all of which will further reshape how moderate to severe AD is managed across the age spectrum.

References

1. FDA approves Lilly's Ebglyss (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis. News release. Eli Lilly and Company. June 9, 2026. Accessed September 10, 2026. https://tinyurl.com/mrbmp9v4

2. FDA accepts supplemental new drug application for Arcutis' Zoryve (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in infants down to 3 months. News release. Arcutis Biotherapeutics. July 8, 2026. Accessed September 10, 2026. https://tinyurl.com/kn5mjez6

3. LEO Pharma announces key results of phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis. News release. LEO Pharma. July 9, 2026. Accessed September 10, 2026. https://tinyurl.com/2u3dftfe

4. American Academy of Dermatology issues first-ever pediatric atopic dermatitis guidelines, highlighting prevention strategies and effective treatments. News release. American Academy of Dermatology. April 7, 2026. Accessed September 10, 2026. https://tinyurl.com/3w7stzx4

5. Turn Therapeutics announces final stage 2 design and data-driven expansion of GX-03 phase 2 program in atopic dermatitis. News release. Turn Therapeutics. July 7, 2026. Accessed September 10, 2026. https://tinyurl.com/26wbj3h5

6. Kymera Therapeutics completes enrollment in the phase 2b BROADEN2 trial of KT-621 in atopic dermatitis with topline data by year-end 2026. News release. Kymera Therapeutics. June 25, 2026. Accessed September 10, 2026. https://tinyurl.com/yc8pmkak

7. Nektar announces publication in The Lancet of positive phase 2b REZOLVE-AD 16-week induction results of rezpegaldesleukin in moderate-to-severe atopic dermatitis. News release. Nektar Therapeutics. August 25, 2026. Accessed September 10, 2026. https://tinyurl.com/5466ttha

8. Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews. News release. Sanofi. July 24, 2026. Accessed September 10, 2026. https://tinyurl.com/2s3tuwvf

9. Kyowa Kirin announces discontinuation of rocatinlimab clinical trials. News release. Kyowa Kirin. March 3, 2026. Accessed September 10, 2026. https://tinyurl.com/5n6vr5rs